Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro

Emil Chteinberg; Suzan Wetzels; Wouter Gerritsen; Lieve Temmerman; Joost van den Oord; Erik Biessen; Anna Kordelia Kurz; Veronique Winnepenninckx; Martin Zenke; Ernst-Jan Speel; Axel zur Hausen

doi:10.1177/1758835920975621

Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro

Emil Chteinberg, Suzan Wetzels, Wouter Gerritsen, Lieve Temmerman, Joost van den Oord, Erik Biessen, Anna Kordelia Kurz, Veronique Winnepenninckx, Martin Zenke, Ernst-Jan Speel, Axel zur Hausen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	1758835920975621
Number of pages	16
Journal	Therapeutic Advances in Medical Oncology
Volume	12
DOIs	https://doi.org/10.1177/1758835920975621
Publication status	Published - Dec 2020

Keywords

apoptosis
BCL-2 inhibitor
Merkel cell carcinoma
Merkel cell polyomavirus
PI3K inhibitor
BCL-XL
EXPRESSION
APOPTOSIS
POLYOMAVIRUS
CHEMOTHERAPY
PROTEINS
PI3K
P53
PHARMACOKINETICS
MALIGNANCIES

Access to Document

10.1177/1758835920975621Licence: CC BY-NC

Cite this

Chteinberg, E., Wetzels, S., Gerritsen, W., Temmerman, L., van den Oord, J., Biessen, E., Kurz, A. K., Winnepenninckx, V., Zenke, M., Speel, E-J., & Hausen, A. Z. (2020). Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. Therapeutic Advances in Medical Oncology, 12, [1758835920975621]. https://doi.org/10.1177/1758835920975621

Chteinberg, Emil ; Wetzels, Suzan ; Gerritsen, Wouter ; Temmerman, Lieve ; van den Oord, Joost ; Biessen, Erik ; Kurz, Anna Kordelia ; Winnepenninckx, Veronique ; Zenke, Martin ; Speel, Ernst-Jan ; Hausen, Axel zur. / Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. In: Therapeutic Advances in Medical Oncology. 2020 ; Vol. 12.

@article{a6ad65c2b8524bacb407264a1937957b,

title = "Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro",

keywords = "apoptosis, BCL-2 inhibitor, Merkel cell carcinoma, Merkel cell polyomavirus, PI3K inhibitor, BCL-XL, EXPRESSION, APOPTOSIS, POLYOMAVIRUS, CHEMOTHERAPY, PROTEINS, PI3K, P53, PHARMACOKINETICS, MALIGNANCIES",

author = "Emil Chteinberg and Suzan Wetzels and Wouter Gerritsen and Lieve Temmerman and {van den Oord}, Joost and Erik Biessen and Kurz, {Anna Kordelia} and Veronique Winnepenninckx and Martin Zenke and Ernst-Jan Speel and Hausen, {Axel zur}",

year = "2020",

month = dec,

doi = "10.1177/1758835920975621",

language = "English",

volume = "12",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. / Chteinberg, Emil; Wetzels, Suzan; Gerritsen, Wouter; Temmerman, Lieve; van den Oord, Joost; Biessen, Erik; Kurz, Anna Kordelia; Winnepenninckx, Veronique; Zenke, Martin; Speel, Ernst-Jan ; Hausen, Axel zur.

In: Therapeutic Advances in Medical Oncology, Vol. 12, 1758835920975621, 12.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro

AU - Chteinberg, Emil

AU - Wetzels, Suzan

AU - Gerritsen, Wouter

AU - Temmerman, Lieve

AU - van den Oord, Joost

AU - Biessen, Erik

AU - Kurz, Anna Kordelia

AU - Winnepenninckx, Veronique

AU - Zenke, Martin

AU - Speel, Ernst-Jan

AU - Hausen, Axel zur

PY - 2020/12

Y1 - 2020/12

KW - apoptosis

KW - BCL-2 inhibitor

KW - Merkel cell carcinoma

KW - Merkel cell polyomavirus

KW - PI3K inhibitor

KW - BCL-XL

KW - EXPRESSION

KW - APOPTOSIS

KW - POLYOMAVIRUS

KW - CHEMOTHERAPY

KW - PROTEINS

KW - PI3K

KW - P53

KW - PHARMACOKINETICS

KW - MALIGNANCIES

U2 - 10.1177/1758835920975621

DO - 10.1177/1758835920975621

M3 - Article

C2 - 33403016

VL - 12

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

M1 - 1758835920975621

ER -